The RLS Global Board of Directors has resolved to initiate a strategic review process to enable the commercial roll out of ChloraSolv across European markets.

RLS Global announced earlier today that RLS Global and Convatec have agreed to terminate the collaboration agreement. RLS Global and Convatec have agreed that both parties will work jointly and with the common target to have a smooth handover from Convatec to RLS Global.

 

The RLS Global Board of Directors will consider all strategic options, including a partnership, a sale of the company, a sale of ChloraSolv, or a financial investment in RLS Global.

 

"The review process will be undertaken with immediate effect, and we have set no timeline for completion of this process", says Lars Johansson, Chairman of the Board, RLS Global.

"Bringing ChloraSolv to patients will require resources and capital that RLS Global does not have as of today, and hence we are now initiating a strategic review process," Lars Johansson continues.

RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the contact person, 09-11-2023 22:15 CET.

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.

FOR MORE INFORMATION, PLEASE CONTACT:
Lars Johansson, Chairman of the Board, RLS Global
E-mail: larsakehjalmar@gmail.com
Phone: +46 70 588 81 90

Roland Frösing, acting CEO, RLS Global
E-mail: roland.frosing@rlsglobal.se
Phone: +46 723 20 61 00

ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at rls.global

https://news.cision.com/rls-global-ab/r/rls-global-initiates-strategic-review-process-aiming-to-commercialize-chlorasolv,c3873106

(c) 2023 Cision. All rights reserved., source Press Releases - English